Cencora Inc.'s stock soared 5.16% during intraday trading on Thursday, reflecting strong investor sentiment towards the drug distribution sector.

The surge appears to be driven by positive industry trends highlighted in peer company Cardinal Health's earnings report, which showed robust demand for high-margin specialty medicines that treat complex conditions like cancer and autoimmune diseases. Drug distributors including Cencora are benefiting from biosimilar opportunities arising from patent expirations of blockbuster drugs.

Industry analysts note that drug distributors are expanding their presence in the specialty medicines market through strategic acquisitions, diversifying beyond traditional drug distribution while complementing their core businesses. The sector's strong growth outlook and perceived undervaluation are attracting investor interest despite broader healthcare services volatility.